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Context. Endothelium guarantees the vascular homeostasis by the opposite action of 
substances with vasodilating/anti-thrombogenic and vasoconstricting/prothrombotic 
activities. Obesity is characterized by endothelial dysfunction associated with a condition of 
vascular low-grade inflammation.  
Evidence Acquisition. Analysis of available basic or clinical papers published in peer-
reviewed international journals on microcirculation and obesity.   
Evidence Synthesis. Vascular low-grade inflammation which characterizes obesity is 
secondary to abnormal production of proinflammatory cytokines, including tumour necrosis 
factor-alpha (TNF-α). TNF-α, generated either in small vessels or within the perivascular 
adipose tissue (PVAT) of obese patients, stimulates the reactive oxygen species generation, 
mainly through NAD(P)H oxidase activation, which in turn reduces nitric oxide (NO) 
availability. These aspects are lighted by the insulin resistance status and macronutrient 
intake which characterize the obesity condition. Oxidant excess has also been proposed as a 
mechanism whereby TNF-α interferes with the Endothelin-1/NO system at the level of small 
vessels from obese patients. 
Conclusions. In obesity, microvasculature from visceral fat is an important source of low-
grade inflammation and oxidative stress that, together with the PVAT, directly contribute to 
vascular changes, favouring the development and acceleration of the vascular 
atherothrombotic process in this clinical condition.   
the aim of the present review is to report critically the state of the art of the mechanisms accounting 
for the functional alterations of the microvasculature in human obesity. 
INTRODUCTION 
The microcirculation, which includes small arteries, arterioles and capillaries, represents a 
key network to support adequate tissue perfusion and metabolism. The tone of resistance 
vessels has a crucial role in dissipating the pulsatile energy generated by the heart 
contraction, thus protecting small capillaries from pressure damage.  This energy dissipation 
is achieved at the cost of an increase in peripheral vascular resistances, making the regulation 
of the vascular tone at this level one of the most important determinants of blood pressure 
values (1). Accordingly, vascular dysfunction which characterises several pathological 
conditions largely involves adaptive changes at this vascular bed.  
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The endothelium represents a fundamental tissue which guarantees the vascular 
homeostasis by the opposite action of substances with vasodilating/anti-thrombogenic 
properties and vasoconstricting/prothrombotic activities (2). In healthy conditions, the most 
important compound generated by endothelial cells and influencing vascular homeostasis is 
nitric oxide (NO). This is a gas produced by the activity of the constitutive endothelial 
enzyme NO synthase (eNOS) under the influence of chemical or mechanical forces. Among 
these, the most characterised are the activities of endothelial agonists (e.g. acetylcholine, 
bradykinin) acting on specific endothelial receptors, and the shear stress (3). NO exerts its 
cardiovascular (CV) protective role by relaxing media-smooth muscle cells, inhibiting 
platelet adhesion and aggregation, preventing leukocyte adhesion and migration into the 
arterial wall, muscle cell proliferation, and adhesion molecule expression (2, 3).  
In the presence of major CV risk factors, the endothelium loses its protective role, 
switching to a pro-atherosclerotic phenotype. This condition, called “endothelial 
dysfunction”, is characterised by either a reduced production of NO or a predominant 
vascular generation of vasoconstricting and pro-atherosclerotic substances, generically 
termed endothelium-derived contracting factors (EDCFs) (4). These include reactive oxygen 
species (ROS), mainly superoxide, that are generated by different intracellular sources 
according to clinical conditions and vascular districts, including nicotinamide dinucleotide 
phosphate (NADPH) oxidase, cyclooxygenase, xanthine oxidase, and the mitochondria (5, 6). 
Superoxide rapidly reacts with NO to form the highly reactive intermediate peroxynitrite 
which, in turn, determines vascular changes limiting NO bioavailability. Superoxide may also 
stimulate the expression of endothelin-1 (ET-1), another EDCF that binds to specific 
receptors located on both endothelial and smooth muscle cells (ETA and ETB), mediating the 
vast majority of its biological effects (6, 7).  
Recently, a key role played by low-grade vascular inflammation on endothelial 
dysfunction and atherosclerosis emerged (8, 9). In particular, TNF-α has been suggested as a 
key cytokine involved in reducing NO availability, an effect exerted by both inducing ROS 
generation and direct inhibition of eNOS activity (8).  
Obesity is a complex chronic disease associated with increased CV morbidity and 
mortality (10). The earliest manifestation of CV disease in obesity is endothelial dysfunction, 
an alteration that has been documented in several different vascular beds (11-15). A condition 
of chronic low-grade inflammation secondary to the abnormal production of proinflammatory 
cytokines, including TNF-α (16, 17), is considered the main mechanisms leading to 
endothelial dysfunction in obesity. This review aims to give a brief overview of the known 
mechanisms involved in the pathogenesis of endothelial dysfunction in the microcirculation 
of patients with obesity, along with an attempt to address the complex links between visceral 
adiposity, TNF-α and microcirculation.  
OBESITY AND ENDOTHELIAL DYSFUNCTION 
To date, some experimental and human studies have homogeneously documented the 
presence of endothelial dysfunction in obesity (18, 19). A large body of literature indicates 
that obesity is responsible for direct detrimental effects on the vasculature, independently 
from the concomitant presence of traditional CV risk factors commonly detected in obesity, 
including hypertension, diabetes mellitus or dyslipidaemia. The first demonstration that 
obesity per se can cause endothelial dysfunction was reported by Steinberg et al (11), who 
documented reduced endothelium-dependent vasodilation to methacholine in the leg 
microcirculation of obese patients. In line with these results, Perticone et al identified a linear 
relationship between severity of obesity and reduction of endothelial function in the forearm 
microcirculation of overweight-obese patients (13). Importantly, in this study the intra-
arterial infusion of ascorbic acid was able to ameliorate response to acetylcholine, thus 
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suggesting a role of oxidative stress in mediating endothelial dysfunction. Similarly, de Jongh 
et al. (20) demonstrated by iontophoresis technique that small cutaneous vessels of obese 
women have a reduced vasodilating response to acetylcholine, but not to sodium 
nitroprusside, as compared to healthy controls, and that this alteration was detectable in both 
basal conditions and during hyperinsulinemia. In this study, vascular response to 
acetylcholine was directly related to insulin sensitivity and inversely related to blood pressure 
values, suggesting that a reduced endothelial function might contribute to the development of 
microangiopathy associated to obesity and insulin resistance in this vascular bed. Growing 
literature also investigated the endothelial function in resistance vessels isolated from a 
biopsy of abdominal subcutaneous tissue or visceral fat of patients with severe obesity, by an 
in vitro ex-vivo technique. These studies concordantly documented a dramatic reduction of 
endothelium-dependent relaxation of small resistance arteries from obese patients compared 
to lean controls (14, 15, 21).  In particular, it was observed that the blunted response to 
acetylcholine was resistant to the eNOS inhibitor Nω-nitro-L-arginine methylester (L-
NAME), and potentiated by the antioxidant tempol, which also restored the inhibitory effect 
of L-NAME on the endothelial agonist (15). These findings demonstrate that oxidative stress 
might have a greater influence on the NO availability in such vascular bed than the intrinsic 
activity of the eNOS.  
More recently, the presence of an independent impact of obesity on microcirculation was 
further confirmed by van der Heijden et al (22). These authors showed that, in patients with 
treated metabolic risk factors and suspected coronary artery disease, body mass index was 
significantly associated with decreased endothelium-dependent vasodilatation measured with 
peripheral arterial tonometry and laser Doppler flowmetry. Notably, this relationship 
remained highly significant even after adjustment for confounding risk factors, including 
diabetes mellitus, hypertension, hypercholesterolemia, and smoking. 
In conclusions, concordant findings emerging from several vascular beds and consequent 
to different endothelial stimuli demonstrate that microvascular circulation represents a major 
target for obesity-related endothelial dysfunction. In isolated resistance vessels, in which the 
mechanisms accounting for endothelial dysfunction have been explored, a blunted activity of 
NO secondary to oxidant excess was demonstrated.  
Obesity and Inflammation: the role of perivascular adipose tissue (PVAT) 
Over the past decade, a fundamental breakthrough in the obesity-related cardiovascular 
disease was the discovery that obesity is associated with a chronic, low grade, systemic 
inflammatory exposure. While multiple pathways could account for this elevated 
inflammatory burden detected in obesity, the adipose tissue is emerging as a central source of 
pro-inflammatory cytokine production. This affirmation was first proposed by Hotamisligil et 
al (23) showing that TNF-α was constitutively expressed by adipose tissue, over-expressed in 
obesity, and acting as a potential mediator of insulin resistance in several animal models. 
From this pioneering observation, many studies confirmed that human obesity is an 
inflammatory disease, also providing important insights into the mechanisms underlying the 
chronic activation of the immune-inflammatory response in obese patients. It has been 
documented that circulating mononuclear cells and inflammatory cells infiltrating the adipose 
tissue of obese patients adopt a proinflammatory phenotype (24), which is characterised by an 
elevated and dysregulated production of proinflammatory cytokines. Beyond the contribution 
of the immune-inflammatory cells, the visceral fat is increasingly recognised as a major 
source of pro-inflammatory chemokines, named adipokines. The generation of adipokines by 
fat cells can be regarded as an endocrine function and makes the adipose tissue the largest 
endocrine organ of the body, particularly in patients affected by severe obesity. Major 
adipokines generated by fat cells include leptin, resistin and adiponectin (25), all of which 
can influence, through several mechanisms, vascular homeostasis. Leptin is the main protein 
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produced by adipocytes, and its blood concentration is proportional to the amount of adipose 
tissue. In vitro studies suggested that leptin could cause an increment of oxidative stress 
production in endothelial cells (26). Moreover, leptin can stimulate the secretion of TNF-α 
and interleukin-6 (IL-6) which, in turn, may induce endothelial dysfunction (27). Other 
reports, conversely, suggested that leptin might induce vasorelaxation, an effect which 
seemed to be mediated by mechanisms involving the production of the endothelium-derived 
hyperpolarizing factor (28, 29). The ability of leptin to stimulate vasodilation by NO -
independent or -dependent mechanisms requires, however, further investigation, as available 
evidence is conflicting. For example, while Matsuda et al showed a NO-independent 
vasorelaxation of human coronary arteries after infusion of leptin (30), Tsuda et al 
documented an influence of NO-dependent pathways on the endothelial vasorelaxation 
obtained with leptin (31).  
Resistin, produced by adipogenesis, is involved in the development of insulin resistance 
and obesity (32). Recently, it was observed that endothelial cells incubated with human 
recombinant resistin increase their production of ET-1 and the expression of adhesion 
molecules (33), a finding suggesting a direct effect of resistin on vascular endothelium. Most 
convincing evidence on the effects of adipokines on the vascular wall involves the role of 
adiponectin. This adipokine, produced in mature adipocytes, has opposite effects than leptin 
and resistin. Indeed, adiponectin stimulates insulin sensitivity (34), reduces the expression of 
adhesion molecules on the endothelium, inhibits the transformation of macrophages into 
foam cells and reduces the smooth muscle cells proliferation. A study including hypertensive 
patients documented that circulating levels of adiponectin are inversely related to the severity 
of the endothelial dysfunction measured at the level of forearm microcirculation (35). Obesity 
is characterised by reduced production and activity of adiponectin (36), potentially reducing 
the protective effects of this adipokine against the development of endothelial dysfunction 
and the atherosclerotic process.  
A major mechanism whereby obesity can induce vascular changes involves the PVAT, 
which exerts deleterious effects on the vasculature by secreting TNF-α and IL-6 (37). 
Experimental reports indicated TNF-α might stimulate ROS production via activation of 
NAD(P)H oxidase (38), or by the activation of nuclear transcription factor-kappa B (NF-kB) 
(39). This leads to mobilisation and activation of macrophages, migration and proliferation of 
smooth muscle cells, and induction of adhesion molecule expression by the endothelial and 
smooth muscle cells of the vascular wall (40). IL-6 can increase the ROS production by 
activating xanthine oxidase and NAD(P)H oxidase. IL-6 also stimulates liver synthesis of C-
reactive protein, which reduces NO production by decreasing the expression of eNOS (41). 
An increased expression of TNF-α and the acquisition of a pro-oxidant phenotype by PVAT 
might represent common mechanisms leading to vascular changes in condition of insulin 
resistance. Indeed, PVAT from a rodent model of metabolic syndrome shows an increased 
TNF-α generation, together with a decreased adiponectin expression, a greater NADPH 
oxidase activity and a reduced expression of antioxidant ·O2− dismutase (-1, -2, and -3). 
(42).  
In humans, many studies contribute to our understanding a possible link between TNF-α 
and obesity-related vascular dysfunction. In patients with obesity-related metabolic 
syndrome, Tesauro et al (43) assessed the effects of TNF-α neutralisation by infliximab, a 
monoclonal antibody blocking the TNF-α signalling, on vascular reactivity during 
hyperinsulinemia. At baseline, patients showed a reduced relaxation to both acetylcholine and 
sodium nitroprusside during hyperinsulinemia, compared with control subjects. Infliximab 
potentiated the vascular responses to both agonists. Of note, the antioxidant ascorbic acid 
improved the vasodilator response to acetylcholine in obese patients, with no further 
potentiating effect when infliximab was concomitantly administrated. These results indicate 
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that TNF-α inhibition may ameliorate vascular reactivity in obese patients during 
hyperinsulinemia, an effect consequent to a decreased oxidative stress (43). 
More recently, an interesting study conducted in isolated resistance vessels evidenced a 
specific role of PVAT-derived inflammation in the pathogenesis of vascular dysfunction. 
Small arteries with and without PVAT were obtained from a subcutaneous gluteal fat biopsy 
of obese and control subjects. While in vessels of lean controls PVAT was able to generate 
factors that potentiated NO availability, in obese subjects, which showed an increased area of 
adipocytes, the presence of PVAT did not improve vasodilation (44). Acute injection of TNF-
α and IL-6 around healthy blood vessels reduced dilator activity of PVAT, resulting in no 
longer differences compared to the obese group. Pre-incubation of ROS scavengers or 
cytokine antagonist was able to prevent these alterations (44). Taken together, these results 
evidence that in physiological conditions adipocytes contribute to the regulation of local 
vascular tone by modulating NO availability. Adipocyte hypertrophy, oxidant excess and an 
increased accumulation of TNF-α in the PVAT of obese subjects result in a loss of this 
important regulations. These data highlight the pivotal role of inflammation as a promoter of 
vascular dysfunction, being an important mechanism whereby the pathological adipose tissue 
exerts a deleterious effect on the surrounding vasculature in a paracrine manner.  
Does vasculature represent a mere target of PVAT-derived TNF-α?  
Based on current evidence, therefore, PVAT is emerging as a direct regulator of vascular tone 
throughout the generation of pro-inflammatory cytokines with documented direct deleterious 
effects on the vasculature, including TNF-α. These data strengthen the concept of obesity as 
an inflammatory state and indicate vasculature as a potential target of adipose tissue-derived 
inflammatory cytokines. However, whether low-grade inflammation result also from the 
generation of pro-inflammatory products at the level of the vasculature, as well as their 
possible effects on vascular endothelial function in human obesity remain to be elucidated. A 
recent study conducted in our laboratory attempted to respond to these uncertainties. Small 
arteries were isolated from visceral fat immediately after collection of a biopsy sample during 
laparoscopic surgery, in patients with and without severe obesity. Vessels from the obese 
group showed a reduced endothelium-dependent relaxation, which was resistant to L-NAME. 
This blunted relaxation was reversed by the superoxide scavenger tempol and, to a similar 
extent, by infliximab (15). These data were corroborated by the direct measure of the vascular 
wall superoxide anion concentration performed at the confocal microscope after staining with 
the fluorescent probe dihydroethidium. Vessels from the obese group showed higher levels of 
superoxide anions compared to the non-obese group, which was dramatically reduced by 
incubation with tempol or infliximab. Immunohistochemistry indicated a marked up-
regulation of TNF-α mainly in the media layer of these vessels, demonstrating for the first 
time that the vascular wall may also be a source of TNF-α involved in endothelial 
dysfunction. Taken together, these results demonstrate that small vessels from obese patients 
show a reduced NO availability secondary to excess ROS generation and that TNF-α 
promotes endothelial dysfunction by stimulating intravascular ROS generation. In the same 
study, we explored the potential pathway(s) involved in TNF-α-induced vascular ROS 
generation, focusing on the role of NAD(P)H oxidase, inducible nitric oxide synthase (iNOS) 
and xanthine oxidase. Using the specific inhibitors of these enzymes (apocynin, S-
methylisothiourea and allopurinol), we found that only the inhibition of NAD(P)H oxidase 
and iNOS, but xanthine oxidase, could restore the impaired endothelial function in the obese 
group. Similarly, the inhibition of NAD(P)H oxidase and iNOS led to a significant reduction 
of the intravascular superoxide generation as assessed by dihydroethidium. Comprehensively, 
these results suggest that NAD(P)H oxidase and iNOS are the two major enzymatic pathways 
mediating the increase of vascular wall oxidative stress induced by TNF-α in obesity (15).   
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Role of insulin and insulin resistance status on vascular inflammation 
In the past two decades, several evidence suggested that insulin might have an important role 
in regulating vascular homeostasis, over and above the control of local and systemic 
metabolism. It is now recognised that insulin has vasodilatory effects on arteries, veins and 
microcirculation (45-47). Several studies convincingly documented that such effects are 
mainly mediated by an increased stimulation and expression of eNOS within endothelial 
cells, which results in an increased NO availability (48, 49). Over and above its direct effect 
on eNOS, insulin might influence NO availability also by controlling systemic and local 
levels of inflammation and oxidative stress. The expression of the key pro-inflammatory 
transcription factor NF-KB  is suppressed by insulin, particularly within the endothelial cell, 
and this leads to a reduced vascular inflammation (50-52). Insulin also suppresses ROS 
generation by inhibiting the NADPH oxidase activity (51). Based on these findings, it is not 
surprising that conditions of insulin resistance (such as in human obesity) lead to ROS 
generation, vascular inflammation and inhibition of eNOS expression (53). TNF-α has an 
important role in promoting vascular inflammation and oxidative stress due to an altered 
vascular activity of insulin, as it can reduce the insulin signal by inhibiting the expression of 
the insulin receptors (54). Thus, over and above its direct effects, the TNF-α might also 
influence the vascular homeostasis of obese patients by reducing the insulin signal and its 
anti-inflammatory and anti-oxidative effects on the vascular wall.  
Additional support to the presence of a strong relationship between inflammation, insulin 
resistance and vascular changes in obesity is provided by the evidence that an excessive 
macronutrient intake, primary cause of an excessive body weight, results in an increase in 
ROS generation and inflammatory response (52, 55), as well as increment in plasma 
endotoxin concentrations and the expression of Toll-Like receptors (56). Long-term caloric 
restriction and diet-induced weight loss, by contrast, result in the fall of pro-inflammatory 
cytokines, including TNF-α, and this is accompanied by a reduced insulin release after 
glucose challenge (16, 17). Similarly, the reduced inflammation and insulin resistance which 
follows bariatric surgery (57) are associated to a fall in the circulating levels of molecules 
with a negative impact on the vascular homeostasis, including ET-1, elements of the renin-
angiotensin system, and neprilysin (58). 
Local inflammation in obesity: the role of ET-1  
In healthy conditions, ET-1 participates to the vascular homeostasis by binding with two 
receptor subtypes, ETA and ETB. ETA receptors are represented only on smooth muscle cells 
and mediate contractions and promote growth. In contrast, ETB receptors are located on 
smooth muscle cells (where they evoke contractions) and on endothelial cells (where they 
induce relaxation stimulating NO production). Although in physiological condition the NO 
counterbalances the contracting effect of ET-1 (7, 59), in obesity a vascular ET-1/NO 
imbalance is commonly detected. Indeed, Cardillo C et al (60) observed that intra-arterial 
infusion of an ETA receptor blocker (BQ-123) resulted in significant vasodilation at the level 
of the forearm microcirculation from overweight and obese but not in lean hypertensive 
subjects or normotensive control subjects irrespective of their body mass. The BQ-123-
induced vasodilation was significantly related to body mass in hypertensive subjects but not 
in control subjects, thereby indicating a selective enhancement of ETA-dependent 
vasoconstrictor tone in hypertensive patients with increased body mass (60). These findings 
suggest a potential role of the activated ET-1 system in the pathophysiology of complications 
of obesity-related hypertension. The upregulated production of ET-1 in obesity might result 
from the activation of various vascular pathways. Among these, experimental evidence 
indicated that oxidative stress is one of the most important factors stimulating the increase of 
ET-1 synthesis in human coronary artery smooth muscle cells. In turn, ET-1 signal is able to 
stimulate ROS production in the vascular wall, potentially creating a vicious cycle.  
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2018-00512/5078438 by U
niversitÃ  degli studi di Padova - Biblioteca di Storia user on 26 Septem
ber 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00512 
 
 
7
The evidence obtained by Amiri et al in transgenic mice with endothelium-targeted 
overexpression of human preproET-1 strengthened the hypothesis of a positive feedback loop 
between ET-1 signal and oxidative stress. In this model, preproET-1 overexpression causes 
remodelling and inflammation of resistance vessels in the absence of a blood pressure 
elevation, an effect mediated by multiple mechanisms, including the activation of vascular 
NAD(P)H oxidase (61, 62). The increased production of ET-1 under conditions of increased 
vascular oxidative stress also raises the hypothesis that local inflammation might interfere 
with the ET-1-mediated vascular tone in obesity. Oxidant excess can be hypothesized as a 
mechanism whereby TNF-α interferes with the ET-1/NO system. Such possibility was 
recently addressed in our laboratory, aiming to evaluate whether TNF-α contributes to the 
vasoconstriction induced by endogenous ET-1 in small arteries isolated from the visceral 
abdominal fat of patients with severe obesity, and whether this effect might be indirectly 
mediated by a modulation of tonic NO release. Endogenous ET-1 activity was assessed by 
the ETA blocker BQ-123, while the anti-TNF-α infliximab and L-NAME were utilised to test 
TNF-α and NO, respectively. Obese showed a blunted L-NAME-induced vasoconstriction, 
which was improved by pre-incubation with infliximab. Also, BQ-123 induced a greater 
relaxation in the obese group, which resulted to be unaffected by L-NAME but attenuated by 
infliximab. Of note, PVAT removal reversed these effects. Incubation of the vessel with the 
NAD(P)H oxidase inhibitor apocynin, L-NAME, or BQ-123 induced a significant reduction 
of the superoxide excess within the vascular wall of obese patients, and a similar effect was 
obtained when the TNF-α signalling was blocked with infliximab (63). We also detected an 
increased vascular expression of ET-1, ETA, and ETB receptors, and higher 
vascular/perivascular TNF-α and TNF-α receptor expression (63). These complex results 
provided the first evidence that in small arteries from obese patients, the ET-1/NO imbalance 
is mediated by vascular and perivascular TNF-α excess, coupled with an increased vascular 
expression of ET-1 and ETA receptor. Such alterations induce endothelial dysfunction, which 
is characterised by ROS excess and impair tonic NO release in the vascular wall. These 
findings also support the concept that in obesity PVAT loses its vascular protective properties 
switching towards a functionally active pro-contractile inflammation source. 
Conclusions 
Obesity is characterised by a marked endothelial dysfunction caused by a reduced NO 
availability. In this clinical condition, PVAT plays a crucial role in generating pro-
inflammatory cytokines, including TNF-α, with a documented direct deleterious effect 
toward the vasculature. In particular, while TNF-α promotes superoxide generation in the 
vascular wall via different pathways, the most important contribution might be due to the 
hyperactivation of the NAD(P)H oxidase. In such a scenario, crucial roles are played by the 
insulin resistance status and the chronic macronutrient intake, which contribute to the 
obesity-associated chronic inflammatory status. TNF-α also participates in the ET-1/NO 
imbalance in small arteries from obese patients (Figure 1). At present, the available literature 
does not enable establishing whether the small arteries and adipocytes located within PVAT 
should be regarded as independent and coexisting sites of TNF-α generation or, by contrast, 
whether there is a hierarchical relationship or mutual interplay between these two districts. 
Any extrapolation of the potential effects of visceral fat on the small vessels to other vascular 
beds requires caution, as the vascular responses to the autocrine/paracrine functions of the 
endothelium can vary depending on the anatomical location of blood vessels. Nevertheless, 
there is no doubt that these findings recognise obesity as an inflammatory condition and 
identify the microvasculature from visceral fat an important source of low-grade 
inflammation and oxidative stress that, together with the PVAT, directly contribute to the 
local development of insulin resistance.  
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Figure 1. Schematic diagram showing the hypothetic mechanisms whereby TNF-α induces 
vascular changes in small vessels from obese patients. In condition of visceral obesity, 
chronic low-grade vascular inflammation generated by PVAT and/or within vasculature 
stimulates the reactive oxygen species (ROS) generation, through NAD(P)H oxidase 
activation and other sources, which in turn reduces the NO availability. TNF-α also directly 
stimulates ET-1 generation, that exerts a mutual stimulation with ROS.  
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